Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
24.36
-1.03 (-4.06%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Palvella Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022
Period Ending
Dec '24 Dec '23 Dec '22
Selling, General & Admin
5.943.084.16
Research & Development
8.158.7913.88
Operating Expenses
14.111.8718.04
Operating Income
-14.1-11.87-18.04
Interest Expense
-4.32--10.36
Interest & Investment Income
-6.27-
Other Non Operating Income (Expenses)
-0.121.2-0.17
EBT Excluding Unusual Items
-18.53-4.41-28.58
Other Unusual Items
1.123.1-
Pretax Income
-17.4318.69-28.58
Income Tax Expense
---1.03
Net Income
-17.4318.69-27.55
Preferred Dividends & Other Adjustments
-14.81-
Net Income to Common
-17.433.88-27.55
Shares Outstanding (Basic)
226
Shares Outstanding (Diluted)
226
Shares Change (YoY)
24.08%-68.63%-
EPS (Basic)
-7.832.19-4.82
EPS (Diluted)
-7.832.17-4.82
EBIT
-14.1-11.87-18.04
Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q